American Medical Systems Europe B.V., guaranteed by Boston Scientific Corporation, filed a free writing prospectus on November 19, 2026, disclosing the terms of a multi-tranche euro-denominated senior notes offering totaling up to €4,250,000,000, with proceeds intended primarily to finance the Penumbra Acquisition.

Key Highlights

  • Total offering size: €4,250,000,000 in senior notes across multiple tranches, issued by American Medical Systems Europe B.V. and guaranteed by Boston Scientific Corporation.
  • Floating Rate Notes (2-year): €500,000,000 principal, priced at 100.000% of par, bearing interest at three-month EURIBOR plus 63 basis points, maturing December 1, 2028.
  • 2028 Fixed Rate Notes (2-year): €500,000,000 principal, priced at 99.870% of par, coupon of 3.875% per annum, yield to maturity of 3.944%, maturing December 1, 2028.
  • 2030 Fixed Rate Notes (4-year): €750,000,000 principal, priced at 99.852% of par, coupon of 4.125% per annum, yield to maturity of 4.166%, maturing December 1, 2030.
  • Settlement date: December 1, 2026 (T+8), through Clearstream Banking S.A. and Euroclear Bank SA/NV.
  • Issuer ratings: A3 / A- / A- (Moody's / S&P / Fitch), with outlooks of Negative / Negative / Stable, according to the filing.
  • Use of proceeds: The filing states proceeds are intended to finance the cash consideration for the Penumbra Acquisition and related fees, with any excess for general corporate purposes.

Terms of the American Medical Systems Europe Multi-Tranche Euro Notes Offering

According to the free writing prospectus filed on November 19, 2026, American Medical Systems Europe B.V. priced three tranches of SEC-registered senior notes under Registration Statement No. 333-285032. Boston Scientific Corporation acts as guarantor for all tranches. The notes are expected to be listed on the Official List of the Irish Stock Exchange plc for trading as Euronext Dublin and admitted to the Global Exchange Market thereof, as described in the filing.

The 2-year Floating Rate Notes carry a principal amount of €500,000,000 and pay interest quarterly in arrears beginning March 1, 2027, at the applicable EURIBOR rate plus 63 basis points, with a minimum interest rate of 0.000% per annum. The calculation agent is U.S. Bank Europe DAC. Except in connection with certain tax events, the filing states the Floating Rate Notes are not redeemable prior to maturity. The 2-year Fixed Rate 2028 Notes also total €500,000,000, priced at 99.870%, with a 3.875% annual coupon paid annually on December 1, beginning December 1, 2027. The spread to mid-swaps is 53 basis points, and the spread to the benchmark Bund (OBL 2.400% due October 19, 2028) is 74.6 basis points, according to the filing.

The filing also discloses a special mandatory redemption provision applicable to the 2028 Fixed Rate Notes: if the Penumbra Acquisition is not completed by the Special Mandatory Redemption End Date, or if Boston Scientific notifies the trustee it will not pursue completion, the 2028 Notes must be redeemed at 101% of aggregate principal plus accrued and unpaid interest. The filing further notes that substantially concurrently, Boston Scientific intends to offer dollar-denominated notes in a separate transaction, though "the completion of the USD Notes offering is not a condition to the completion of this offering." Barclays Bank PLC serves as joint bookrunner and stabilization manager across all tranches.

What Was Disclosed

American Medical Systems Europe B.V. disclosed the pricing terms for at least three tranches of euro-denominated senior notes totaling part of a €4,250,000,000 offering, guaranteed by Boston Scientific Corporation, with proceeds earmarked primarily for the Penumbra Acquisition.